Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Almirall To Put More Skin In The Game With Derma Buys

Executive Summary

The Spanish company has a lot riding on tildrakizumab, the psoriasis drug licensed from Sun Pharma which could get the green light in Europe before year-end. Until then, Almirall is scouring the market for bolt-on deals.


Related Content

Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina
Ilumya Becomes Sun's New Branded Specialty Drug Pillar
Fourth Act For AbbVie's Risankizumab Whets Appetite
Almirall Knocked Back By US Woes, Could Affect Other Companies Too
Almirall To Position Oral DMF For Psoriasis Ahead Of EU Biologics Use


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts